Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Queensland Health
UBS
Fuji
Cantor Fitzgerald
Boehringer Ingelheim
US Army
QuintilesIMS
Healthtrust
Cipla

Generated: February 24, 2018

DrugPatentWatch Database Preview

Thalidomide - Generic Drug Details

« Back to Dashboard

What are the generic sources for thalidomide and what is the scope of thalidomide freedom to operate?

Thalidomide
is the generic ingredient in one branded drug marketed by Celgene and is included in one NDA. There are fifteen patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Thalidomide has forty-seven patent family members in nineteen countries.

There are nine drug master file entries for thalidomide. One supplier is listed for this compound.
Pharmacology for thalidomide
Medical Subject Heading (MeSH) Categories for thalidomide

US Patents and Regulatory Information for thalidomide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-001 Jul 16, 1998 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-001 Jul 16, 1998 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for thalidomide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-001 Jul 16, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-001 Jul 16, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-001 Jul 16, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for thalidomide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,006,267 Pharmaceutical compositions and dosage forms of thalidomide ➤ Try a Free Trial
6,767,326 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for thalidomide

Supplementary Protection Certificates for thalidomide

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/039 United Kingdom ➤ Try a Free Trial PRODUCT NAME: THALIDOMIDE (INTERNATIONAL NON-PROPRIETARY NAME) 2-(2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLINE-1,3-DIONE (SYSTEMATIC (IUPAC) NAME); REGISTERED: UK EU/1/08/443/001 20080416
C0036 France ➤ Try a Free Trial PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
C0036 France ➤ Try a Free Trial PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
00358 Netherlands ➤ Try a Free Trial PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Teva
US Army
Deloitte
Farmers Insurance
Chinese Patent Office
Argus Health
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot